High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.

被引：1
|
作者：
Oner, Gizem [1 ]
Onder, Semen [1 ]
Karatay, Huseyin [1 ]
Tukenmez, Mustafa [1 ]
Muslumanoglu, Mahmut [1 ]
Igci, Abdullah [1 ]
Dinccag, Ahmet [1 ]
Ozmen, Vahit [1 ]
Aydiner, Adnan [1 ]
Yavuz, Ekrem [1 ]
Cabioglu, Neslihan [1 ]
机构：
[1] Istanbul Univ, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24136
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
    Oner, Gizem
    Onder, Semen
    Karatay, Huseyin
    Ak, Naziye
    Tukenmez, Mustafa
    Muslumanoglu, Mahmut
    Igci, Abdullah
    Dinccag, Ahmet
    Ozmen, Vahit
    Aydiner, Adnan
    Yavuz, Ekrem
    Cabioglu, Neslihan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [2] Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
    Gizem Oner
    Semen Önder
    Hüseyin Karatay
    Naziye Ak
    Mustafa Tükenmez
    Mahmut Müslümanoğlu
    Abdullah İğci
    Ahmet Dincçağ
    Vahit Özmen
    Adnan Aydiner
    Ekrem Yavuz
    Neslihan Cabioğlu
    World Journal of Surgical Oncology, 19
  • [3] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
    Miyashita, M.
    Sasano, H.
    Tamaki, K.
    Hirakawa, H.
    Ishida, T.
    Ohuchi, N.
    BREAST, 2017, 32 : S100 - S101
  • [4] Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
    Gizem Oner
    Semen Önder
    Hüseyin Karatay
    Naziye Ak
    Mustafa Tükenmez
    Mahmut Müslümanoğlu
    Abdullah İğci
    Ahmet Dincçağ
    Vahit Özmen
    Adnan Aydiner
    Ekrem Yavuz
    Neslihan Cabioğlu
    World Journal of Surgical Oncology, 21
  • [5] Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
    Basik, Mark
    Roseshter, Talia
    Klemantovich, Anna
    Cavallone, Luca
    Aguilar-Mahecha, Adriana
    Lafleur, Josiane
    Lan, Cathy
    Elebute, Oluwadara
    Jenna, Sarah
    Boileau, Jean-Francois
    Pelmus, Manuela
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
    Luen, S. J.
    Salgado, R.
    Dieci, M. V.
    Vingiani, A.
    Curigliano, G.
    Gould, R. E.
    Castaneda, C.
    D'Alfonso, T.
    Sanchez, J.
    Cheng, E.
    Andreopoulou, E.
    Castillo, M.
    Adams, S.
    Demaria, S.
    Symmans, W. F.
    Michiels, S.
    Loi, S.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 236 - 242
  • [7] Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
    Parsons, H. A.
    Blewett, T.
    Chu, X.
    Sridhar, S.
    Santos, K.
    Xiong, K.
    Abramson, V. G.
    Patel, A.
    Cheng, J.
    Brufsky, A.
    Rhoades, J.
    Force, J.
    Liu, R.
    Traina, T. A.
    Carey, L. A.
    Rimawi, M. F.
    Miller, K. D.
    Stearns, V.
    Specht, J.
    Falkson, C.
    Burstein, H. J.
    Wolff, A. C.
    Winer, E. P.
    Tayob, N.
    Krop, I. E.
    Markrigiorgos, G. M.
    Golub, T. R.
    Mayer, E. L.
    Adalsteinsson, V. A.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 899 - 906
  • [8] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Clémence Pinard
    Marc Debled
    Houda Ben Rejeb
    Valérie Velasco
    Christine Tunon de Lara
    Stéphanie Hoppe
    Elodie Richard
    Véronique Brouste
    Hervé Bonnefoi
    Gaëtan MacGrogan
    Breast Cancer Research and Treatment, 2020, 179 : 11 - 23
  • [9] Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
    Pinard, Clemence
    Debled, Marc
    Ben Rejeb, Houda
    Velasco, Valerie
    Tunon de Lara, Christine
    Hoppe, Stephanie
    Richard, Elodie
    Brouste, Veronique
    Bonnefoi, Herve
    MacGrogan, Gaetan
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 11 - 23
  • [10] Residual Cancer Burden After Neoadjuvant Chemotherapy in Breast Cancer Patients
    Elder, E. A.
    Livasy, C.
    Donahue, E.
    Neelands, B. J.
    Patrick, A.
    Needham, M.
    Sarantou, T.
    Hadzikadic-Gusic, L.
    White, R.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S53 - S53
12345